INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Feb 03, 2006 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 16,000 | -- | -- |
Feb 03, 2006 |
SVP, PreclinDevel & Biomol Sci
Trans History: 660
|
SVP, PreclinDevel & Biomol Sci | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 24,000 | -- | -- |
Feb 01, 2006 |
Director
Trans History: 282
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,246 | $12.00 | 1,836 |
Feb 01, 2006 |
Director
Trans History: 282
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 1,246 | $15.24 | 590 |
Feb 01, 2006 |
Director
Trans History: 282
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 2,071 | $12.00 | 2,661 |
Feb 01, 2006 |
Director
Trans History: 282
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 2,071 | $15.25 | 590 |
Feb 01, 2006 |
Director
Trans History: 282
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 2,968 | $12.00 | 3,558 |
Feb 01, 2006 |
Director
Trans History: 282
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 2,968 | $15.30 | 590 |
Feb 01, 2006 |
Director
Trans History: 282
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,465 | $12.00 | 2,055 |
Feb 01, 2006 |
Director
Trans History: 282
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 1,465 | $15.40 | 590 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.